SCHEMBL2685104

SCHEMBL2685104

O=C(O)NC(Cc1ccc(Cl)cc1)C(=O)Nc1cc(-c2ccncc2)no1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR142 Q7Z601 4/20 0.58
▸ MAPT P10636 5/20 0.52
▸ ROCK2 O75116 2/20 0.42
▸ ROCK1 Q13464 2/20 0.42
▸ PRKACA P17612 1/20 0.42
▸ RPS6KB1 P23443 1/20 0.42
▸ IRAK1 P51617 1/20 0.42
▸ PRKX P51817 1/20 0.42
▸ LIMK1 P53667 1/20 0.42
▸ PRKG2 Q13237 1/20 0.42
▸ PRKG1 Q13976 1/20 0.42
▸ PKN2 Q16513 1/20 0.42
▸ HIPK4 Q8NE63 1/20 0.42
▸ AURKB Q96GD4 1/20 0.42
▸ CLK4 Q9HAZ1 1/20 0.42
▸ CSNK1G1 Q9HCP0 1/20 0.42
▸ ERAP2 Q6P179 1/20 0.41
▸ ERAP1 Q9NZ08 1/20 0.41
▸ LNPEP Q9UIQ6 1/20 0.41
▸ USP30 Q70CQ3 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2684501 0.90 GPR142 (0.69) GPR142MAPTRORCMEN1NPC1
SCHEMBL2684100 0.86 GPR142 (0.50) GPR142MAPTMME
SCHEMBL2684105 0.86 GPR142 (0.50) GPR142MAPTMME
SCHEMBL2685679 0.84 GPR142 (0.58) GPR142MAPTROCK2ROCK1PRKACA
SCHEMBL2685674 0.84 GPR142 (0.58) GPR142MAPTROCK2ROCK1PRKACA
SCHEMBL25254658 0.81 MME (0.46) GPR142MAPTROCK2ROCK1PRKACA
SCHEMBL25215967 0.81 MME (0.46) GPR142MAPTROCK2ROCK1PRKACA
SCHEMBL25254663 0.81 MME (0.46) GPR142MAPTROCK2ROCK1PRKACA
SCHEMBL2683472 0.80 GPR142 (0.62) GPR142
SCHEMBL2683481 0.80 GPR142 (0.62) GPR142

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 — — US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS IAPP, INSR, AMY2A GPR142 2779/4885MAPT 4112/4885ROCK2 2870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback